Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles ...
FDA Drug Recall #D-0617-2024 — Class II — June 21, 2024
Recall Summary
| Recall Number | D-0617-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 21, 2024 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Zydus Pharmaceuticals (USA) Inc |
| Location | Pennington, NJ |
| Product Type | Drugs |
| Quantity | a) 13,128 bottles; b) 252 bottles |
Product Description
Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles (NDC 68382-034-16) and b)1000-count bottles (NDC 68382-034-10), Rx only, Mfg. by: Zydus Lifesciences Ltd. Ahmedabad, India; Dist. by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534
Reason for Recall
Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals.
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot #: a) M213175, Exp. Date 09/2024; b) M213176, Exp. Date 09/2024
Other Recalls from Zydus Pharmaceuticals (USA) Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0400-2026 | Class II | Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... | Mar 9, 2026 |
| D-0295-2026 | Class II | Icosapent Ethyl capsules, 1 gram, 120-count bot... | Dec 30, 2025 |
| D-0247-2026 | Class III | traZODONE Hydrochloride Tablets, USP, 100mg, 1,... | Dec 19, 2025 |
| D-0159-2026 | Class II | Bromocriptine Mesylate Capsules, USP, 5 mg, 30 ... | Oct 23, 2025 |
| D-0152-2026 | Class II | clomiPRAMINE Hydrochloride, Capsules, USP, 25 m... | Oct 22, 2025 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.